- Home
- ACIU vs ENGN Comparison
ACIU vs ENGN Comparison
Compare ACIU & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- ENGN
- Stock Information
- Founded
- ACIU 2003
- ENGN 1999
- Country
- ACIU Switzerland
- ENGN Canada
- Employees
- ACIU N/A
- ENGN N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- ENGN
- Sector
- ACIU Health Care
- ENGN
- Exchange
- ACIU Nasdaq
- ENGN Nasdaq
- Market Cap
- ACIU 332.4M
- ENGN 317.6M
- IPO Year
- ACIU 2016
- ENGN N/A
- Fundamental
- Price
- ACIU $2.71
- ENGN $6.14
- Analyst Decision
- ACIU Strong Buy
- ENGN Strong Buy
- Analyst Count
- ACIU 2
- ENGN 9
- Target Price
- ACIU $12.00
- ENGN $29.78
- AVG Volume (30 Days)
- ACIU 130.0K
- ENGN 214.2K
- Earning Date
- ACIU 11-05-2024
- ENGN 12-19-2024
- Dividend Yield
- ACIU N/A
- ENGN N/A
- EPS Growth
- ACIU N/A
- ENGN N/A
- EPS
- ACIU N/A
- ENGN N/A
- Revenue
- ACIU $48,505,404.00
- ENGN N/A
- Revenue This Year
- ACIU $85.33
- ENGN N/A
- Revenue Next Year
- ACIU $80.69
- ENGN N/A
- P/E Ratio
- ACIU N/A
- ENGN N/A
- Revenue Growth
- ACIU 4097200.00
- ENGN N/A
- 52 Week Low
- ACIU $2.25
- ENGN $4.42
- 52 Week High
- ACIU $5.14
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- ACIU 29.89
- ENGN 34.84
- Support Level
- ACIU $2.62
- ENGN $5.60
- Resistance Level
- ACIU $3.07
- ENGN $6.54
- Average True Range (ATR)
- ACIU 0.15
- ENGN 0.70
- MACD
- ACIU -0.04
- ENGN -0.11
- Stochastic Oscillator
- ACIU 17.24
- ENGN 17.70
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.